Genekam develops plasma therapy accelerator for Covid-19 patients
Genekam Biotechnology has developed a plasma therapy accelerator called SARS-Hunter, which enables hospitals to isolate antibodies from plasma to be given as therapy for Covid-19 patients.
Genekam Biotechnology has developed a plasma therapy accelerator called SARS-Hunter, which enables hospitals to isolate antibodies from plasma to be given as therapy for Covid-19 patients.
Antibodies, which are isolated from plasma using SARS-Hunter, are normally rich in coronavirus (SARS-Cov-2)-specific antibodies. The antibodies can be administered to the patient after running simple safety tests, particularly for bacterial contamination.
Plasma from recovered Covid-19 patients is being used as an effective therapeutic option to treat virus-infected patients.
However, plasma therapy may cause a number of side effects, including allergic reactions, infections of other pathogens, acute lung injuries and red blood cell lysis.
Genekam’s device increases the chances of treatment success while reducing the side effects of currently existing plasma therapy. It isolates antibodies in less than one hour.
SARS-Hunter is the quickest solution for the creation of effective antibody therapy with low costs for all patients around the world, the company noted.
As millions of recovered Covid-19 patients can donate their plasma multiple times a year, it will allow more Covid-19 patients to undergo antibody therapy.
Plasma donors with high-quality neutralising corona-specific antibodies are said to create effective therapeutic doses. It can be given to more patients instead of giving the whole plasma to one patient.
SARS-hunter weighs approximately 400gm and is very simple to operate.
It is expected to have a very strong impact on antibody therapy and make it available to a large population of Covid-19 patients.
Genekam has priced SARS-Hunter and reagentsat $1,499.